BusinessUK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia ABy Nasdaq OMXOct 13, 2016, 8:01 PM UTC
BusinessBioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy ProgramBy Nasdaq OMXApr 20, 2016, 12:30 PM UTC
